Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE

• A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treat…
• https://x.com/RichardPAConway/status/1857848106349412762/photo/1

A systematic review highlights the impact of glucocorticoids (GC) during pregnancy and lactation. Increased risks of preterm birth were noted with GC exposure, advocating for minimized doses and pregnancy-compatible treatments. Encouragingly, low levels of GC found in breast milk… https://t.co/7CnJUBrUDQ https://t.co/ZeGHFHNT13

• https://x.com/i/web/status/1857842318214148429
• https://x.com/synovialjoints/status/1857842318214148429/photo/1

Does apremilast have cardiometabolic benefits? Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo

• https://x.com/AkhilSoodMD/status/1857829735235035286/photo/1

Data from the study by Dr. Aguilar et al showed that high dose NSAID use was not assoc'd with incident HTN in their cohort of early axSpA patients. Shows important role of NSAIDs in #axSpA but still should be used judiciously @RheumNow #ACR24 abs540 @rheum_cat @rheumarhyme https://t.co/LK5yFZynu4

• https://x.com/RHEUMarampa/status/1857827589999526276/photo/1

Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz

• Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patie…
• https://x.com/RichardPAConway/status/1857824199076884798/photo/1

Data from the French DESIR cohort reveals no significant link between high-dose NSAID use and incident hypertension in patients with axial spondyloarthritis. Two thirds were high dose NSAID users at baseline. Incident hypertension occurred in 11% individuals during follow-up.… https://t.co/EAICDwzxNT

• https://x.com/i/web/status/1857823444974374951

Pasoto et al. Holding MMF for 1 week after zoster vaccine (RZV) improves response with no increase in flare @RheumNow #ACR24 Abstr#0247 https://t.co/q757bMFp7I https://t.co/rwjz3q3MaO

• Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week…
• https://x.com/RichardPAConway/status/1857817404069523767/photo/1

Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7

• https://x.com/JihaRheum/status/1857813377805893719/photo/1

Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW

• https://x.com/EBRheum/status/1857807337664426337/photo/1
• https://x.com/EBRheum/status/1857807337664426337/photo/1

Which immunomodulators dampen recombinant zoster vaccine immunogenicity? In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are: - rituximab pts - 'combined therapy' strategies needed for them but reassuring for the others! #ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg

• https://x.com/drdavidliew/status/1857804958550339997/photo/1